NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Gritstone bio, Inc.
The average one-year price target for Gritstone Bio (NASDAQ:GRTS) has been revised to 10.71 / share. This is an increase of 22.09% from the prior estimate of 8.77 dated August 31, 2023. The price ...
Gritstone bio's GRANITE program shows promising preliminary results in the treatment of metastatic microsatellite stable colorectal cancer (MSS-CRC). The data suggests that GRANITE could be an ...
Hosted on MSN
B. Riley Securities Downgrades Gritstone bio (GRTS)
Fintel reports that on October 2, 2024, B. Riley Securities downgraded their outlook for Gritstone bio (NasdaqGS:GRTS) from Buy to Neutral. Analyst Price Forecast Suggests 1,880.58% Upside As of ...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Gritstone ...
NEW YORK, July 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS). Shareholders who purchased shares of GRTS during the class ...
Gritstone bio (NASDAQ:GRTS) was downgraded by both Jones Research and B. Riley on Wednesday, the day after the stock cratered in the wake of mixed data for Gritstone’s GRANITE cancer vaccine and news ...
NEW YORK, NY / ACCESSWIRE / July 9, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, ...
Fintel reports that on September 28, 2023, Piper Sandler maintained coverage of Gritstone Bio (NASDAQ:GRTS) with a Overweight recommendation. As of August 31, 2023, the average one-year price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback